Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart and Anlotinib in Elderly Patients With Advanced NSCLC
NCT07849712Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of benmelstobart and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Objective Response Rate at 24 months and Incidence and Severity of Adverse Events at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07849712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07849712.